Abstract Number: 2890 • 2014 ACR/ARHP Annual Meeting
Does a Family History of RA Influence the Clinical Presentation and Treatment Response in RA?
Background/Purpose: Since family history of RA is among the strongest risk factors for developing the disease, individuals suspected to have RA are routinely asked about…Abstract Number: 2838 • 2014 ACR/ARHP Annual Meeting
Exploratory Analysis of Pharmacokinetic Effects of Atacicept in Patients with Moderate to Severe Systemic Lupus Erythematosus
Background/Purpose: Atacicept is a fusion protein that inhibits B-cell stimulating factors BLyS and APRIL. We previously reported the clinical effects of atacicept in lupus patients…Abstract Number: 2522 • 2014 ACR/ARHP Annual Meeting
Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations
Background/Purpose To evaluate the effects of infliximab (Ifx) dose increase in active rheumatoid arthritis (RA) patients, presenting different serum infliximab concentrations.Methods Retrospective study including 42…Abstract Number: 2515 • 2014 ACR/ARHP Annual Meeting
Serum Survivin in Early Rheumatoid Arthritis
Background/Purpose: The proto-oncogene survivin regulates cell division and inhibits apoptosis. Elevated levels may be found in patients with rheumatoid arthritis (RA) and their presence has…Abstract Number: 2502 • 2014 ACR/ARHP Annual Meeting
Ten Year Follow-up Results of Four Dynamic Treat to Target Strategies in Patients with ACPA Negative Rheumatoid Arthritis
Background/Purpose: To determine the optimal treatment strategy in patients with anti-citrullinated protein antibodies (ACPA) negative (‒) rheumatoid arthritis (RA), as it has been suggested that…Abstract Number: 2513 • 2014 ACR/ARHP Annual Meeting
The Monitoring of Infliximab Levels at Early Stages Can Predict the Development of Anti-Infliximab Antibodies in a Cohort of Rheumatoid Arthritis Patients Treated with Infliximab
Background/Purpose : There is a close association between serum Infliximab (Ifx) levels and the Antibodies To Infliximab (ATI) with the clinical activity in rheumatoid arthritis…Abstract Number: 2478 • 2014 ACR/ARHP Annual Meeting
Analysis of the Clinical Sustained Response after Retreatment with a Lower Dose of Rituximab in Patients with Chronic Inflammatory Arthropathies
Background/Purpose: The dosage of rituximab (RTX) approved for the treatment of active rheumatoid arthritis (RA) is two intravenous (iv.) 1 g infusions, separated by two…Abstract Number: 2489 • 2014 ACR/ARHP Annual Meeting
Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) decreases in mean peripheral neutrophil count were…Abstract Number: 1312 • 2013 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity Score Correlates With Radiographic Progression In Early Rheumatoid Arthritis: Results From a Randomized Trial
Background/Purpose: In early rheumatoid arthritis (eRA), predictors of radiographic damage would be useful for optimal targeting of therapy. It has been suggested that combining various…Abstract Number: 876 • 2013 ACR/ARHP Annual Meeting
Prediction Of TNF Inhibitor Response In Rheumatoid Arthritis Patients Using Single Cell Network Profiling Of Intracellular Immune Signaling
Background/Purpose: Biomarkers predictive of drug efficacy are lacking in rheumatoid arthritis (RA) and would be useful in clinical practice and clinical trials. Single cell…Abstract Number: 790 • 2013 ACR/ARHP Annual Meeting
Predictors and Sustainability Of Clinical Inactive Disease In Polyarticular Juvenile Idiopathic Arthritis Given Aggressive Therapy Very Early In The Disease Course
Background/Purpose: The double-blind, randomized placebo-controlled Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT) compared the ability of 2 aggressive treatment regimens to…Abstract Number: 472 • 2013 ACR/ARHP Annual Meeting
Clinical Efficacy Rate Of The Non-Specific Effect (the placebo effect) In The Tumour Necrosis Factor Inhibitors For Rheumatoid Arthritis Treatment After Methotrexate Failure: Meta-Analysis
Background/Purpose: Therapeutics generate non-specific effects (the placebo effect), and specific ones, like the 5 tumor necrosis factor (TNF) inhibitors used in the treatment of Rheumatoid…Abstract Number: 2687 • 2013 ACR/ARHP Annual Meeting
Very High Remission Rates Are Achieved By Methotrexate and Intraarticular Glucocorticoids Independent Of Induction Therapy With Adalimumab; Year 2 Clinical Results Of An Investigator-Initiated Randomised, Controlled Clinical Trial Of Early, Rheumatoid Arthritis (OPERA)
Background/Purpose: In a double-blind placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis (RA), we investigated if additional adalimumab (ADA) for 1 year on…Abstract Number: 428 • 2013 ACR/ARHP Annual Meeting
Correlation Between Objective and Patient Self-Reported Clinical Improvement After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: Data From Repeat Study
Background/Purpose: Rituximab (RTX) has been evaluated in many clinical trials and objective assessment of rheumatoid arthritis (RA) activity must comply with Treat to Target principles.…Abstract Number: 2377 • 2013 ACR/ARHP Annual Meeting
Biomarkers Associated With Rheumatoid Arthritis Disease Activity Including Joint Damage Correlate With Changes In Clinical Response In Subjects Treated With Mavrilimumab At Doses Above 10 Mg
Background/Purpose: GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through effects on macrophages and neutrophils. Mavrilimumab (CAM-3001) is a human monoclonal…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- Next Page »